Chromosomal Changes in Patients with Multiple Myeloma (MM)

Multiple Myeloma (plasma cell myeloma, myelomatosis or Kahler's disease) is a chronic, progressive, and lethal disease characterized with plasma cells was increased uncontrolled that produced monoclonal immunoglobulin (M protein) in bone marrow. In the last 10 years, especially in genetics, technological developments have resulted in dramatic progress in myeloma biology and treatment. Enrichment of cellular and molecular details for disease has led to new initiatives and principles leading to choice of treatment. The disease prognosis is determined by variables such as the morphology, biology, function, and genetic characteristics of the cells that make up the disease. Nowadays, genetic features are taken into account in determining prognosis and selection of treatment. Development of MM; is defined as a multi-step event triggered by mutations, chromosomal translocations, certain viral infections and possibly the effects of various genetic abnormalities. It has been observed that complex genetic anomalies increase with the progression of the disease. Genetic changes will be helpful not only in terms of clinical prognosis but also in choosing therapeutic alternatives by anticipating the response to be taken from the treatment